Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C3H5O3.Ca |
| Molecular Weight | 218.218 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O
InChI
InChIKey=MKJXYGKVIBWPFZ-UHFFFAOYSA-L
InChI=1S/2C3H6O3.Ca/c2*1-2(4)3(5)6;/h2*2,4H,1H3,(H,5,6);/q;;+2/p-2
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlCurator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details
Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension? | 1999 Jul 30 |
|
| Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
| Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
| Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
| Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. | 2000 Aug |
|
| Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. | 2000 Dec |
|
| D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. | 2000 Dec 15 |
|
| Inactivation properties of human recombinant class E calcium channels. | 2000 Feb |
|
| A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
| Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. | 2000 May |
|
| Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
| Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
| Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
| Molecular and functional characterization of a family of rat brain T-type calcium channels. | 2001 Feb 9 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. | 2001 Jul |
|
| Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. | 2001 Jun |
|
| [Acute renal failure caused by hypercalcemia]. | 2001 Jun 10 |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
| Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
|
| Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate. | 2018 Mar |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12AA05
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
||
|
CFR |
21 CFR 184.1207
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-327
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
||
|
JECFA EVALUATION |
INS-327
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
||
|
WHO-ATC |
A12AA05
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
||
|
EPA PESTICIDE CODE |
298
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2URQ2N32W3
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
4383
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
CHEMBL2106111
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
13144
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
976
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
100000092155
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
212-406-7
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
DB13231
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
2URQ2N32W3
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
C110051
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
m2950
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
CALCIUM LACTATE
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
814-80-2
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
47622
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB13184MIG
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
1086888
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
C76830
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
DTXSID0020236
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY | |||
|
747
Created by
admin on Sat Dec 16 10:07:12 GMT 2023 , Edited by admin on Sat Dec 16 10:07:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
